Search research articles
Contact Us
Filters
Showing results (241-250 of 263) with videos related to
Page
of 27
Sort By:
Haematologica
|
January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation study
Eli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 11, 2019
Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes
Geetha Ramachandran, Padmapriyadarshini Chandrasekaran, Sanjay Gaikwad, et al.
Emerging Infectious Diseases
|
January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020
Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 15, 2015
Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel
Amita Gupta, Jyoti S Mathad, Susan M Abdel-Rahman, et al.
Nature Communications
|
September 30, 2025
Aberrant intermediate alveolar epithelial cells promote pathogenic activation of lung fibroblasts in preclinical fibrosis models
Evan T Hoffman, Anit Shah, Willy Roque Barboza, et al.
Nature Communications
|
January 12, 2024
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial
Evanthia Galanis, Katharine E Dooley, S Keith Anderson, et al.
Research Square
|
April 8, 2025
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Linda Harrison, Gustavo E Velasquez, Russell R Kempker, et al.
Trials
|
August 15, 2025
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 263) with videos related to
Sort By:
Page
of 27
Haematologica
|
January 15, 2026
Hepatic response criteria in light chain amyloidosis: a multicenter validation study
Eli Muchtar, Giovanni Palladini, Stefan Schonland, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 11, 2019
Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes
Geetha Ramachandran, Padmapriyadarshini Chandrasekaran, Sanjay Gaikwad, et al.
Emerging Infectious Diseases
|
January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020
Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 15, 2015
Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel
Amita Gupta, Jyoti S Mathad, Susan M Abdel-Rahman, et al.
Nature Communications
|
September 30, 2025
Aberrant intermediate alveolar epithelial cells promote pathogenic activation of lung fibroblasts in preclinical fibrosis models
Evan T Hoffman, Anit Shah, Willy Roque Barboza, et al.
Nature Communications
|
January 12, 2024
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial
Evanthia Galanis, Katharine E Dooley, S Keith Anderson, et al.
Research Square
|
April 8, 2025
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Linda Harrison, Gustavo E Velasquez, Russell R Kempker, et al.
Trials
|
August 15, 2025
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Page
of 27